

THE CANCER RESEARCH FOUNDATION AND AFFILIATE

COMBINED FINANCIAL STATEMENTS

MARCH 31, 2022

TABLE OF CONTENTS

INDEPENDENT AUDITORS' REPORT..... 3-4

COMBINED FINANCIAL STATEMENTS

Statements of Financial Position 5

Statements of Activities..... 6

Statements of Functional Expenses..... 7

Statements of Cash Flows 8

Notes to Financial Statements..... 9-21

COMBINING SUPPLEMENTARY INFORMATION

Schedule of Financial Position 23

Schedule of Activities..... 24

Schedule of Functional Expenses..... 25



INDEPENDENT AUDITORS' REPORT

Board of Directors
The Cancer Research Foundation and Affiliate
Chicago, Illinois

Opinion

We have audited the accompanying combined financial statements of THE CANCER RESEARCH FOUNDATION AND AFFILIATE (Illinois not-for-profit organizations), which comprise the combined statements of financial position as of March 31, 2022 and 2021, and the related combined statements of activities, functional expenses and cash flows for the years then ended, and the related notes to the combined financial statements.

In our opinion, the combined financial statements referred to above present fairly, in all material respects, the financial position of THE CANCER RESEARCH FOUNDATION AND AFFILIATE as of March 31, 2022 and 2021, and the changes in their net assets and their cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of THE CANCER RESEARCH FOUNDATION AND AFFILIATE and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the combined financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about THE CANCER RESEARCH FOUNDATION AND AFFILIATE's ability to continue as a going concern within one year after the date that the combined financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements, including omissions, are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of THE CANCER RESEARCH FOUNDATION AND AFFILIATE's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about THE CANCER RESEARCH FOUNDATION AND AFFILIATE's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Supplementary Information

Our 2022 audit was conducted for the purpose of forming an opinion on the combined financial statements as a whole. The supplementary information listed in the accompanying table of contents is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the combined financial statements as a whole.

The image shows a handwritten signature in dark ink that reads "Warady & Davis LLP". The signature is written in a cursive, flowing style.

September 22, 2022

THE CANCER RESEARCH FOUNDATION AND AFFILIATE
COMBINED STATEMENTS OF FINANCIAL POSITION

As of March 31	2022	2021
ASSETS		
CURRENT ASSETS		
Cash	\$ 1,643,893	\$ 183,861
Investments	10,368,442	10,367,714
Accrued Interest Receivable	22,907	22,377
Prepaid Expenses	4,933	1,050
Accrued Excise Taxes Receivable	—	11,495
Total Current Assets	12,040,175	10,586,497
INVESTMENTS HELD IN PERPETUITY	710,265	710,265
OTHER ASSETS		
Security Deposit	1,900	1,900
TOTAL ASSETS	\$ 12,752,340	\$ 11,298,662
LIABILITIES AND NET ASSETS		
CURRENT LIABILITIES		
Grants Payable	\$ 600,000	\$ 610,000
Accounts Payable and Accrued Expenses	31,775	8,248
Total Current Liabilities	631,775	618,248
NET ASSETS		
Net Assets Without Donor Restriction	9,472,937	8,086,846
Net Assets With Donor Restriction	2,647,628	2,593,568
Total Net Assets	12,120,565	10,680,414
TOTAL LIABILITIES AND NET ASSETS	\$ 12,752,340	\$ 11,298,662

COMBINED STATEMENTS OF ACTIVITIES

For the Years Ended March 31

2022

2021

	Without Donor Restriction	With Donor Restriction	Total	Without Donor Restriction	With Donor Restriction	Total
SUPPORT REVENUES						
Contributions	\$ 473,890	\$ —	\$ 473,890	\$ 345,054	\$ —	\$ 345,054
Grants	467,000	—	467,000	—	—	—
Bequests	148,208	—	148,208	30,433	—	30,433
Event Revenues	901,867	—	901,867	—	—	—
Donated Services	18,961	—	18,961	38,806	—	38,806
Donated Auction Items	87,737	—	87,737	—	—	—
Total Support Revenues	<u>2,097,663</u>	<u>—</u>	<u>2,097,663</u>	<u>414,293</u>	<u>—</u>	<u>414,293</u>
OTHER REVENUES						
Interest and Dividends, net	173,086	50,380	223,466	180,996	53,210	234,206
Net Realized and Unrealized Gain on Investments	<u>454,487</u>	<u>153,680</u>	<u>608,167</u>	<u>2,330,715</u>	<u>690,768</u>	<u>3,021,483</u>
Investment Income, net	<u>627,573</u>	<u>204,060</u>	<u>831,633</u>	<u>2,511,711</u>	<u>743,978</u>	<u>3,255,689</u>
Forfeited Grants	<u>114</u>	<u>—</u>	<u>114</u>	<u>22,196</u>	<u>—</u>	<u>22,196</u>
Total Revenues, net	<u>2,725,350</u>	<u>204,060</u>	<u>2,929,410</u>	<u>2,948,200</u>	<u>743,978</u>	<u>3,692,178</u>
FUNCTIONAL EXPENSES						
Program Services	1,027,001	150,000	1,177,001	1,084,753	150,000	1,234,753
Supporting Services						
Management and General	119,691	—	119,691	104,372	—	104,372
Fundraising	122,278	—	122,278	65,487	—	65,487
Special Event Fundraising	86,290	—	86,290	—	—	—
Total Functional Expenses	<u>1,355,260</u>	<u>150,000</u>	<u>1,505,260</u>	<u>1,254,612</u>	<u>150,000</u>	<u>1,404,612</u>
Excise Taxes Benefit	<u>(16,001)</u>	<u>—</u>	<u>(16,001)</u>	<u>(11,495)</u>	<u>—</u>	<u>(11,495)</u>
Total Expenses	<u>1,339,259</u>	<u>150,000</u>	<u>1,489,259</u>	<u>1,243,117</u>	<u>150,000</u>	<u>1,393,117</u>
CHANGE IN NET ASSETS	1,386,091	54,060	1,440,151	1,705,083	593,978	2,299,061
Net Assets, Beginning	8,086,846	2,593,568	10,680,414	6,381,763	1,999,590	8,381,353
NET ASSETS, ENDING	<u>\$ 9,472,937</u>	<u>\$ 2,647,628</u>	<u>\$ 12,120,565</u>	<u>\$ 8,086,846</u>	<u>\$ 2,593,568</u>	<u>\$ 10,680,414</u>

See accompanying notes.

THE CANCER RESEARCH FOUNDATION AND AFFILIATE

COMBINED STATEMENTS OF FUNCTIONAL EXPENSES

For the Years Ended March 31

2022

2021

	Supporting Services				Total	Program Services	Supporting Services		Total
	Program Services	Management and General	Fundraising	Special Event Fundraising			Management and General	Fundraising	
Grants	\$ 845,000	\$ —	\$ —	\$ —	\$ 845,000	\$ 955,000	\$ —	\$ —	\$ 955,000
Payroll and Taxes	238,489	79,497	79,495	—	397,481	200,191	75,954	34,448	310,593
Venue, Food and Entertainment	—	—	—	66,250	66,250	—	—	—	—
Legal and Professional	37,000	22,671	11,335	—	71,006	46,798	16,162	8,080	71,040
Telephone	1,200	856	428	—	2,484	1,388	866	432	2,686
Postage and Office Supplies	15,999	7,649	14,598	580	38,826	8,873	4,212	7,975	21,060
Advertising	15,468	1,476	10,067	—	27,011	11,724	238	7,577	19,539
Rent	3,449	5,273	5,138	—	13,860	3,041	5,146	5,068	13,255
Meeting Expense	5,094	1,273	—	—	6,367	—	—	—	—
Insurance	471	377	95	—	943	1,262	927	128	2,317
Newsletter	752	—	188	—	940	3,591	—	898	4,489
Internet	1,047	386	583	7,115	9,131	2,862	867	881	4,610
Dues and Subscriptions	310	155	310	—	775	—	—	—	—
Miscellaneous	12,722	78	41	12,345	25,186	23	—	—	23
	\$1,177,001	\$ 119,691	\$ 122,278	\$ 86,290	\$1,505,260	\$ 1,234,753	\$ 104,372	\$ 65,487	\$ 1,404,612

See accompanying notes.

THE CANCER RESEARCH FOUNDATION AND AFFILIATE

COMBINED STATEMENTS OF CASH FLOWS

For the Years Ended March 31	2022	2021
CASH FLOWS FROM OPERATING ACTIVITIES		
Change in Net Assets	\$ 1,440,151	\$ 2,299,061
Adjustments to Reconcile Change in Net Assets to Net Cash Provided (Used) by Operating Activities		
Net Realized and Unrealized Gain on Investments	(608,167)	(3,021,483)
Changes in Assets and Liabilities:		
Accrued Interest Receivable	(530)	590
Prepaid Expenses	(3,883)	(1,050)
Accrued Excise Taxes Receivable	11,495	(11,495)
Grants Payable	(10,000)	95,000
Accounts Payable and Accrued Expenses	23,527	(14,296)
Accrued Excise Taxes	—	(16,000)
Total Adjustments	(587,558)	(2,968,734)
Net Cash Provided (Used) by Operating Activities	852,593	(669,673)
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchases of Investments	(1,229,514)	(1,093,758)
Proceeds from Sales of Investments	1,836,953	1,833,962
Net Cash Provided by Investing Activities	607,439	740,204
NET INCREASE IN CASH	1,460,032	70,531
Cash, Beginning	183,861	113,330
CASH, ENDING	\$ 1,643,893	\$ 183,861

NOTES TO COMBINED FINANCIAL STATEMENTS

NATURE OF ORGANIZATION

The Cancer Research Foundation (CRF) is an Illinois not-for-profit corporation, created to raise funds to support early-career scientists and new directions in cancer science research with the goal of contributing to “Transformational Events” in the prevention, treatment and cure for cancer. CRF seeks to leverage the collective knowledge and experience of its employees and board members, its allies and its past grantees, to make grants that have the ability to increase scientific knowledge significantly more than money from traditional funding sources. To do this, CRF employs a two-pronged strategy of relying on some of the best minds in cancer science while keeping its overhead as low as possible.

CRF practices a grant-making strategy intended to allow it to make the greatest difference in cancer knowledge possible. The premier granting vehicle is the CRF Young Investigator Award, a 2-year award totaling \$100,000, and granted to multiple researchers every year focused on bridging the funding gap most starting scientists face. In June of 2016, CRF established a separate Chicago Chapter (the Chapter) (collectively, the Foundation) tasked with fundraising and grant-making exclusively in the Chicago area to further grow this approach.

Effective June 1, 2021, the Chapter entered into an agreement to integrate The Breakthrough Board (TBB), which was formerly called the Women’s Board, and part of a separate charitable organization as defined by Internal Revenue Code 501(c)(3) called the University of Chicago Cancer Research Foundation.

Certain members of CRF’s Board of Directors also serve as the members of the Chapter’s Board of Directors along with 4 members of TBB. The Chapter receives funds from CRF for operational expenses and employs all the funds it raises in grants made to researchers within the Chicago area. Both CRF and the Chapter have been designated as charitable organizations as defined by Internal Revenue Code 501(c)(3) and all donations made to each organization qualify for the maximum charitable contribution allowable.

NOTE 1—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This summary of significant accounting policies is presented to assist in understanding the Foundation’s combined financial statements. The combined financial statements and notes are representations of management who is responsible for their integrity and objectivity. These accounting policies conform to U.S. generally accepted accounting principles (GAAP) and have been consistently applied in the preparation of the financial statements.

BASIS OF ACCOUNTING

The combined financial statements of the Foundation have been prepared on the accrual basis of accounting in accordance with GAAP.

PRINCIPLES OF COMBINATION

The accompanying combined financial statements include the accounts of CRF and the Chapter. All intercompany transactions and balances have been eliminated.

NOTES TO COMBINED FINANCIAL STATEMENTS

NOTE 1—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

FINANCIAL STATEMENT PRESENTATION

Financial statement presentation follows the requirements of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (the FASB Codification) topic related to “Financial Statements of Not-for-Profit Organizations.” This guidance requires the Foundation to report information regarding its financial position and activities, based on the existence or absence of donor-imposed restrictions. Accordingly, net assets of the Foundation and changes therein are classified and reported as follows:

Net assets without donor restriction – Net assets that are not subject to donor-imposed stipulations plus those resources for which donor-imposed stipulations have been satisfied. Net assets without donor restriction may otherwise be designated for specific purposes by action of the Board of Directors.

Voluntary resolutions by the Foundation’s Board of Directors to designate a portion of net assets without donor restriction for specific purposes do not result in restricted funds. Since designations are voluntary and may be reversed by the Board of Directors at any time, Board-designated net assets are considered net assets without donor restriction. As of March 31, 2022 and 2021, the Board of Directors did not designate any net assets without donor restriction for a specific purpose or period.

Net assets with donor restriction – Net assets whose use by the Foundation are subject to donor-imposed stipulations that could be fulfilled either by actions of the Foundation, pursuant to those stipulations and/or that expire by the passage of time. Net assets with donor restriction are reclassified to net assets without donor restriction when the restriction has been met and presented in the combined statements of activities as net assets released from restriction, if any.

Additionally, the Foundation has net assets subject to donor-imposed stipulations for the resources to be maintained permanently by the Foundation. Investment income (loss) earned on such resources is classified as net assets with donor restriction (only to be used for laboratory research) until such amounts are appropriated for expenditure by the Foundation’s Board of Directors in a manner consistent with the standard of prudence prescribed by the Uniform Prudent Management of Institutional Funds Act (UPMIFA).

Revenues are reported as increases in net assets without donor restriction unless use of the related asset is limited by donor-imposed stipulations. Expenses are reported as decreases in net assets without donor restriction. Gains and losses on investments and other assets or liabilities are reported as increases or decreases in net assets without donor restriction unless their use is restricted by explicit donor stipulation or by law.

USE OF ESTIMATES

The preparation of combined financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the combined financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

NOTES TO COMBINED FINANCIAL STATEMENTS

NOTE 1—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

RECOGNITION OF SUPPORT, RECEIVABLES AND REVENUES (Continued)

The Foundation accounts for public support contributions received and unconditional promises to give under the provisions of the FASB Codification topic related to contributions made and received. Contributions are recognized as support revenue when received. Unconditional promises to give, if any, are recognized when received at the estimated present value of future cash flows, net of allowances, if any.

Contributions received are recognized as support revenue with or without donor restriction, depending on the existence and/or nature of any donor stipulations. When a donor restriction expires (that is, when a stipulated time restriction ends or purpose restriction is accomplished), net assets with donor restriction are reclassified to net assets without donor restriction and reported in the combined statements of activities as net assets released from restriction, if any.

Contributions of assets other than cash, if any, are recognized in the combined statements of activities at their estimated fair value at the date of donation. The Foundation is a beneficiary of several estates and trusts maintained by independent trustees. Such bequests represent split-interest agreements, which are recognized as revenue at their estimated future value when the Foundation is notified it has an irrevocable beneficial interest in such agreements. Such beneficial interests in irrevocable trusts are typically the result of distributions to be received upon liquidation of estates and trusts, and are valued at the proportional share of interest, at the closing price reported on the active or observable market on which the trusts' underlying individual securities are traded as reported to the Foundation by the trustees. The gifts are recorded at the fair value of the Foundation's interest in such estates and trusts.

Any proportionate share of interest known, but not yet distributed, is recognized as a receivable at fair value in the combined statements of financial position and any changes in the estimated future value of split-interest agreements are recognized in the combined statements of activities. The Foundation was notified of and recognized bequests of \$148,208 and \$30,433 for the years ended March 31, 2022 and 2021.

CONTRIBUTED GOODS AND SERVICES

Donated auction items, which have reasonably estimable and determinable fair values, are recognized at their estimated fair value on the date the item is donated. During the year ended March 31, 2022, the Chapter, including TBB, hosted an event in two locations and broadcast virtually, for which the Chapter received donated auction items with an estimated fair value of \$87,737, which are included in contributions on the statements of activities.

Donated services received are recognized as revenues at their estimated fair value when they create or enhance nonfinancial assets, or they require specialized skills which would need to be purchased if they were not donated. The Chapter received \$18,961 of donated professional services during the year ended March 31, 2022 and the Foundation received \$38,806 for the year ended March 31, 2021, which are separately included on the statements of activities and included in legal and professional on the statements of functional expenses.

NOTES TO COMBINED FINANCIAL STATEMENTS

NOTE 1—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

CONTRIBUTIONS AND GRANTS MADE

An unconditional promise made by a not-for-profit organization is recognized as grant expense and grant payable in the period that the promise is made, or when the Board of Directors approves the grant. Grants distributed are deemed unconditional, provided the recipient continues their research at a comprehensive research center. Upon departure from the research center, the recipient forfeits the remainder of the grant to the Foundation.

FAIR VALUE MEASUREMENTS

The provisions of the FASB guidance on fair value measurements defines fair value, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The guidance applies to all assets and liabilities that are measured and reported on a fair value basis. The carrying amounts of financial instruments, including cash, accrued interest receivable, grants payable, accounts payable and accrued liabilities, approximate fair value due to the short maturity of these instruments.

INVESTMENTS

The Foundation follows the provisions of the FASB Codification topic related to accounting for investments held by not-for-profit organizations. This standard requires investments in marketable securities be accounted for at fair value on the trade date.

Investment income (loss), net, in the combined statements of activities includes interest income, recognized when earned, and dividend income, recognized on the ex-dividend date, net of custodial and investment advisory fees incurred of \$94,394 and \$82,286 for the years ended March 31, 2022 and 2021, respectively. Also included in investment income (loss) net, are net realized gains and losses, which are the differences between the proceeds received and the cost of investments sold, and unrealized gains and losses, which are the differences between the fair value and cost of investments held.

PROPERTY AND EQUIPMENT

Property and equipment are stated at cost. The Foundation capitalizes all individual expenditures for property and equipment in excess of \$2,500. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from 5-7 years. Maintenance and repairs that do not increase the useful lives of the assets are charged to expense as incurred. Property and equipment totaling \$2,572 was fully depreciated in a prior year, thus no depreciation expense was incurred for the years ended March 31, 2022 and 2021.

FUNCTIONAL ALLOCATION OF EXPENSES

The costs of providing various programs and supporting services are presented on a functional basis in the combined statements of activities. All direct costs are charged to the applicable functional area. Indirect costs are allocated to programs and supporting services based on management estimates, considering the nature of the expense and how it relates to such functional area. Management and general costs include those expenses that are not directly identifiable with any other specific function but provide for the overall support and direction of the Foundation.

Total fundraising expense for the years ended March 31, 2022 and 2021 amounted to \$208,568 and \$65,487. Fundraising expenses are computed using actual expenses and an allocation of expenses based on management's estimate.

NOTES TO COMBINED FINANCIAL STATEMENTS

NOTE 1—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

CONCENTRATIONS OF RISK

The Foundation's cash balances, at times, may exceed federally insured limits, however it has not experienced any losses in these accounts and management believes it is not exposed to any significant credit risk on cash.

Investments are exposed to various risks such as interest rate, market and credit risks. Due to the level of risk associated with investments, it is at least reasonably possible that changes in the fair value of investments will occur in the near term and that such changes could materially affect the financial statements.

CRF is a member of the Combined Federal Campaign and Local Independent Charities of America whereby government employees make donations to selected charities through payroll withholdings. Contributions from such organizations amounted to 37% of total public support for the year ended March 31, 2021.

TAX STATUS

The United States Treasury Department has advised that CRF and the Chapter are not-for-profit corporations organized and operated exclusively for charitable and scientific purposes. The Foundation is exempt from income tax under Section 501(c)(3) of the Internal Revenue Code and applicable State law.

ADVERTISING COSTS

Advertising costs are expensed as incurred. Advertising expenses for the years ended March 31, 2022 and 2021 totaled \$27,011 and \$19,539.

CONDITIONAL CONTRIBUTIONS

In June 2018, the FASB issued ASU No. 2018-08, *Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made*. The guidance applies to all entities that receive or make contributions and clarifies the definition of an exchange transaction. The criteria for evaluating whether contributions are unconditional (and thus recognized immediately as revenue) or conditional (for which revenue recognition is delayed until the condition is met) have been clarified. The focus is whether a gift or grant agreement both (1) specifies a "barrier" that the recipient must overcome to be entitled to the resources and (2) releases the donor from its obligation to transfer resources if the barrier is not achieved. An agreement that includes both is a conditional contribution. The Foundation adopted the ASU commencing April 1, 2019.

As previously disclosed, effective June 1, 2021, the Chapter entered into an agreement to integrate TBB, which was formerly called the Women's Board, part of a separate charitable organization associated with the University of Chicago Cancer Research Foundation. The Chapter received a \$467,000 conditional grant without donor restriction from the original organization to be paid in two installments. The Chapter received the first \$267,000 payment in June of 2021 and \$200,000 was to be paid by January 30, 2022, conditional upon the integrated organization raising \$375,000 gross from May 11, 2021 through December 31, 2021. The fundraising goal was met prior to such date and TBB made the remaining payment in March 2022. As of March 31, 2022, there are no conditional grants or contributions.

NOTES TO COMBINED FINANCIAL STATEMENTS

NOTE 1—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

NEW ACCOUNTING PRONOUNCEMENTS ADOPTED

In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09 (Topic 606): *Revenue from Contracts with Customers*, which supersedes the current revenue recognition requirements in Topic 605, *Revenue Recognition*. The ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The ASU permits application of the new revenue recognition guidance to be applied using one of two retrospective application methods. The new guidance became effective for the Foundation’s year ending March 31, 2022. The standard did not have a significant impact on the Foundation’s combined financial statements.

NEW ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED

In February 2016, the FASB issued ASU No. 2016-02, *Leases (Topic 842)*, which supersedes *ASC 840, Leases*. The ASU requires lessees to recognize a right-of-use asset and related lease liability for all leases, with a limited exception for short-term leases. Leases will be classified as either financing or operating, with the classification affecting the pattern of expense recognition in the statements of activities. Currently, leases are classified as either capital or operating, with only capital leases recognized on the statements of financial position. The reporting of lease-related expenses in the statements of activities and cash flows will be generally consistent with the current guidance. The ASU was effective for annual reporting periods beginning after December 15, 2020 but was extended until annual reporting periods beginning after December 15, 2021. As a result of the COVID-19 pandemic, the FASB extended the effective date of this ASU by one year. The new guidance will be effective for the Foundation’s year ending March 31, 2023 and will be applied using a modified retrospective transition method to the beginning of the earliest period presented. The lease standard is expected to increase assets and lease liabilities upon adoption and there is not expected to be a significant impact on expenses or cash flows. Management has determined that overall, the standard will not have a significant impact on the Foundation’s combined financial statements and is currently gathering the appropriate information to implement the standard in a timely manner.

NOTE 2—LIQUIDITY AND AVAILABILITY OF RESOURCES

Financial assets available for general expenditure, that is, without donor or other restrictions limiting their use, within one year of the statement of financial position date, are comprised of the following at March 31, 2022 and 2021:

	2022	2021
Cash.....	\$ 1,643,893	\$ 183,861
Investments.....	11,078,707	11,077,979
Accrued Interest Receivable.....	22,907	22,377
Less: Net Assets with Donor Restriction	(2,647,628)	(2,593,568)
	\$ 10,097,879	\$ 8,690,649

NOTES TO COMBINED FINANCIAL STATEMENTS

NOTE 2—LIQUIDITY AND AVAILABILITY OF RESOURCES (Continued)

As part of its liquidity management plan, the Foundation maintains sufficient cash in its general operating account to meet current operating needs and invests excess cash in its investment portfolio, composed of a general investments fund without donor restriction and an endowment investments fund with donor restriction. The general operating account is used to collect contributions and pay for general operating expenses, with the goal of maintaining a balance of approximately \$100,000 unless there is a grant payable in the near future. Cash needed in excess of the general operating account is transferred from the general investments fund, which is available for use. The endowment investments fund represents the net assets with donor restriction and is only to be used to fund the Fletcher Award, which are \$100,000 per award over two years, in annual installments of \$50,000 per year per recipient. No Fletcher Awards were named for the year ended March 31, 2022, three Fletcher Awards were issued in the year ended March 31, 2021. As indicated in the above table, the Foundation has sufficient liquid assets to meet at least one year of expenses.

NOTE 3—INVESTMENTS

The Foundation has an investment portfolio recorded at estimated fair value, which is composed of a general investments fund without donor restriction and an endowment investments fund with donor restriction, the corpus of which, in the original amount of \$710,265, is stipulated by the donor to be maintained in perpetuity with income only to be used for laboratory research.

Investments as of March 31, 2022 consisted of:

	General Fund	Endowment Fund	Total
Cash.....	\$ 8,912	\$ 2,441	\$ 11,353
Bank Deposit Program	60,941	115,367	176,308
Common Stocks.....	5,595,465	1,692,488	7,287,953
Corporate Bonds	566,026	230,536	796,562
Preferred Stocks.....	<u>2,205,679</u>	<u>600,852</u>	<u>2,806,531</u>
Total Investments.....	<u>\$ 8,437,023</u>	<u>\$ 2,641,684</u>	<u>\$ 11,078,707</u>

Investments as of March 31, 2021 consisted of:

	General Fund	Endowment Fund	Total
Cash.....	\$ 9,016	\$ 2,621	\$ 11,637
Bank Deposit Program	298,996	112,317	411,313
Common Stocks.....	5,398,214	1,641,049	7,039,263
Corporate Bonds	670,720	299,294	970,014
Preferred Stocks.....	<u>2,113,543</u>	<u>532,209</u>	<u>2,645,752</u>
Total Investments.....	<u>\$ 8,490,489</u>	<u>\$ 2,587,490</u>	<u>\$ 11,077,979</u>

NOTES TO COMBINED FINANCIAL STATEMENTS

NOTE 4—FAIR VALUE MEASUREMENTS

The Foundation accounts for its financial instruments at estimated fair value, in accordance with GAAP, which defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date and sets out a fair value hierarchy. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). Inputs are broadly defined as assumptions market participants would use in pricing an asset or liability. The three levels of the fair value hierarchy are described below:

Level 1: Unadjusted quoted prices for identical assets or liabilities in active markets that the Foundation has the ability to access at the measurement date. The types of investments included in Level 1 include exchange-traded equity securities.

Level 2: Inputs other than quoted prices within Level 1, that are observable for the asset or liability, either directly or indirectly, and the fair value is determined through the use of models or other valuation methodologies. Investments that are generally included in this category include corporate bonds and preferred stocks. A significant adjustment to a Level 2 input could result in the Level 2 measurement becoming a Level 3 measurement.

Level 3: Inputs that are unobservable for the asset or liability and include situations where there is little, if any, market activity for the asset or liability. The Foundation has no Level 3 investments.

The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an investment's level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The Foundation's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. The valuation methods used may produce a fair value calculation that may not be indicative of the net realizable value or reflective of future fair values. Furthermore, although management believes the Foundation's valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. There have been no changes in the methodologies used at March 31, 2022 and 2021. The following is a description of the valuation methodologies used for recurring assets measured at fair value.

Level 1 Fair Value Measurements

The fair value of investments in bank deposit program and exchange-traded common stocks is based on quoted market prices in active markets for identical assets.

NOTES TO COMBINED FINANCIAL STATEMENTS

NOTE 4—FAIR VALUE MEASUREMENTS (Continued)

Level 2 Fair Value Measurements

The fair value of corporate bonds is estimated using various techniques, which may consider recently executed transactions in securities of the issuer or comparable issuers, market price quotations (where observable), bond spreads, fundamental data relating to the issuer, and credit default swap spreads adjusted for any basis difference between cash and derivative instruments. Although most corporate bonds are categorized in Level 2 of the fair value hierarchy, in instances where lower relative weight is placed on transaction prices, quotations, or similar observable inputs, they may be categorized in Level 3.

The fair value of preferred stocks is estimated using the present value of its future income stream discounted at its required yield of rate of return.

Level 3 Fair Value Measurements

The Foundation has no Level 3 fair value measurements.

Fair value of investments measured on a recurring basis at March 31, 2022 is as follows:

	<u>Fair Value</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
Bank Deposit Program	\$ 176,308	\$ 176,308	\$ —	\$ —
Common Stocks.....	7,287,953	7,287,953	—	—
Corporate Bonds	796,562	—	796,562	—
Preferred Stocks.....	<u>2,806,531</u>	<u>—</u>	<u>2,806,531</u>	<u>—</u>
Total Investments, at Fair Value	11,067,354	<u>\$ 7,464,261</u>	<u>\$ 3,603,093</u>	<u>\$ —</u>
Cash.....	<u>11,353</u>			
Total Investments.....	<u>\$ 11,078,707</u>			

Fair value of investments measured on a recurring basis at March 31, 2021 is as follows:

	<u>Fair Value</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
Bank Deposit Program	\$ 411,313	\$ 411,313	\$ —	\$ —
Common Stocks.....	7,039,263	7,039,263	—	—
Corporate Bonds	970,014	—	970,014	—
Preferred Stocks.....	<u>2,645,752</u>	<u>—</u>	<u>2,645,752</u>	<u>—</u>
Total Investments, at Fair Value	11,066,342	<u>\$ 7,450,576</u>	<u>\$ 3,615,766</u>	<u>\$ —</u>
Cash.....	<u>11,637</u>			
Total Investments.....	<u>\$ 11,077,979</u>			

NOTES TO COMBINED FINANCIAL STATEMENTS

NOTE 5—NET ASSETS WITH DONOR RESTRICTION

The Foundation's net assets with donor restriction are composed solely of an endowment investments fund from a single donor, the \$710,265 corpus of which is specified by the donor to be maintained permanently with income only to be used for laboratory research. During the years ended March 31, 2022 and 2021, no amounts were released from restrictions and expended on laboratory research. The endowment investments fund's primary objective is to maintain the principal in perpetuity. As required by GAAP, net assets associated with endowment funds, including any funds designated by the Board of Directors to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

The Foundation adopted investment and spending policies, approved by the Board of Directors, for endowment assets. Those policies attempt to provide a predictable stream of funding to programs supported by its endowment investments fund while also maintaining the purchasing power of such endowment assets over the long-term. Accordingly, the investment process seeks to achieve an after-cost total real rate of return, including investment income as well as capital appreciation, which exceeds the annual distribution with acceptable levels of risk. Endowment assets are invested in a well-diversified asset mix, which includes equity and debt securities. Investment risk is measured in terms of the total endowment investments fund; investment assets and allocation between asset classes and strategies are managed to prevent exposing the fund to unacceptable levels of risk. Actual returns in any given year may vary.

The Board of Directors has interpreted UPMIFA as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment investments fund, absent explicit donor stipulations to the contrary. As a result of this interpretation, the Foundation classifies as net assets with donor restriction (a) the original value of gifts donated to the permanent endowment, (b) the original value of any subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of the donor-restricted endowment investments fund that is not classified as part of the permanent endowment are net assets with donor restrictions. These net assets will be classified as donor-restricted until such amounts are appropriated for expenditure by the Foundation's Board of Directors in a manner consistent with the standard of prudence prescribed by UPMIFA. In accordance with UPMIFA, the Foundation considers the following factors in making a determination to appropriate or accumulate income earned from the donor-restricted endowment investments fund: (1) the duration and preservation of the fund, (2) the purpose of the donor-restricted endowment fund, (3) general economic conditions, (4) the possible effect of inflation and deflation, (5) the expected total return from income and the appreciation of investments, and (6) other resources and policies of the Foundation.

NOTES TO COMBINED FINANCIAL STATEMENTS

NOTE 6—GRANTS AUTHORIZED AND PAYABLE

Grants authorized but unpaid at year-end are reported as liabilities in the combined statements of financial position. The following is a summary of grants authorized during the years ended March 31, 2022 and 2021.

<u>Name</u>	<u>2022</u>	<u>2021</u>
Grants authorized to the University of Chicago were directed to the following researchers:		
Dr. Lev Becker	\$ —	\$ 100,000
Dr. Huanhuan Joyce Chen	—	100,000
Dr. Xavier M. Keutgen	—	100,000
Dr. Olatoyosi Odenike	—	100,000
Dr. Samantha J. Riesnefeld	—	100,000
Dr. Peter A Savage	—	100,000
Dr. Brandon Faubert	100,000	—
Dr. Yuxuan ‘Phoenix’ Miao	100,000	—
Dr. Ari J. Rosenberg	100,000	—
Dr. Weixin Tang	100,000	—
Total	<u>400,000</u>	<u>600,000</u>

Grants authorized to Northwestern University were directed to the following researcher:

Dr. Peiwen Chen	—	100,000
Dr Adam Lin	100,000	—
Total	<u>100,000</u>	<u>100,000</u>

Grants authorized to the Washington University in St. Louis were directed to the following researchers:

Dr. Abby Green	—	100,000
Dr. Allegra A. Petti	—	100,000
Dr. Milan Chheda	25,000	—
Dr. David Y Chen	100,000	—
Dr. Beth A. Helmink	100,000	—
Dr. Patricia R. Pereira	100,000	—
Total	<u>325,000</u>	<u>200,000</u>

NOTES TO COMBINED FINANCIAL STATEMENTS

NOTE 6—GRANTS AUTHORIZED AND PAYABLE (Continued)

<u>Name</u>	<u>2022</u>	<u>2021</u>
International Grants authorized for a Special Project with the University of Chicago Pediatric Cancer Data Commons were directed to the following researchers and the organization:		
Dr. Samuel Vochenbom, MD, PhD	\$ —	\$ 10,000
Dr. Monica Terenziani (Italy)	—	15,000
Dr. Sandra Strauss (England)	—	20,000
Pediatric Cancer Data Commons	—	10,000
Fundacion Perez Scremini	<u>20,000</u>	<u>—</u>
Total	<u>20,000</u>	<u>55,000</u>
Total Grants Authorized	<u>845,000</u>	<u>955,000</u>
Less:		
Grants Authorized Not Issued	—	—
Grants Paid	<u>(855,000)</u>	<u>(860,000)</u>
Net Change	<u>(10,000)</u>	95,000
Grants Payable, Beginning	<u>610,000</u>	<u>515,000</u>
Grants Payable, Ending	<u>\$ 600,000</u>	<u>\$ 610,000</u>

During the years ended March 31, 2022 and 2021, the Foundation received refunds of \$114 and \$42,090, related to grant award amounts issued in prior years not spent because of the COVID-19 pandemic, or because the specific projects were discontinued.

NOTE 7—OPERATING LEASE

On June 15, 2020, the Chapter extended for two years, its obligation for future minimum rental commitments totaling \$25,500 by executing the Fifth Amendment to Lease, a non-cancelable operating lease for office space, now expiring in August 2022. The agreement provides for annual base rent and additional rent related to future increases in the building's operating expenses and real estate taxes. Rent expense during the years ended March 31, 2022 and 2021, totaled \$13,860 and \$13,255.

Aggregate future minimum annual payments required under operating lease commitments are as follows:

March 31, 2023	\$ <u>5,375</u>
----------------	-----------------

As of the date of these statements the Foundation is looking for a new lease in a different location.

NOTES TO COMBINED FINANCIAL STATEMENTS

NOTE 8—RELATED PARTY TRANSACTIONS

During the years ended March 31, 2022 and 2021, the Foundation's Board of Directors and board member related family foundations donated \$257,671 and \$42,750.

CRF shares an address with The Heart Research Foundation, Inc., a related entity through common control. In the normal course of business, the two entities do not transact with each other.

NOTE 9—SUBSEQUENT EVENTS

The Foundation has evaluated subsequent events through September 22, 2022, the date that the financial statements were available for issuance. After March 31, 2022, TBB granted \$706,593 to the University of Chicago Cancer Center to fund various projects. Other than as previously disclosed in Note 7, there were no other subsequent events.

SUPPLEMENTARY INFORMATION

COMBINING SCHEDULE OF FINANCIAL POSITION

As of March 31, 2022

	Without Donor Restriction				With Donor Restriction				Combined Total 2022
	Cancer Research Foundation	Cancer Research Foundation - Chicago Chapter	Eliminations	Total	Cancer Research Foundation	Cancer Research Foundation - Chicago Chapter	Eliminations	Total	
ASSETS									
CURRENT ASSETS									
Cash	\$ 293,130	\$ 1,350,763	\$ —	\$ 1,643,893	\$ —	\$ —	\$ —	\$ —	\$ 1,643,893
Investments	8,437,022	—	—	8,437,022	1,931,420	—	—	1,931,420	10,368,442
Accrued Interest Receivable	16,964	—	—	16,964	5,943	—	—	5,943	22,907
Prepaid Expenses	—	4,933	—	4,933	—	—	—	—	4,933
Due from Affiliate	6,415	—	(6,415)	—	—	—	—	—	—
Total Current Assets	<u>8,753,531</u>	<u>1,355,696</u>	<u>(6,415)</u>	<u>10,102,812</u>	<u>1,937,363</u>	<u>—</u>	<u>—</u>	<u>1,937,363</u>	<u>12,040,175</u>
INVESTMENTS HELD IN PERPETUITY	—	—	—	—	710,265	—	—	710,265	710,265
FIXED ASSETS									
Office Equipment	2,572	—	—	2,572	—	—	—	—	2,572
Accumulated Depreciation	(2,572)	—	—	(2,572)	—	—	—	—	(2,572)
Total Fixed Assets	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>
OTHER ASSETS									
Security Deposit	1,900	—	—	1,900	—	—	—	—	1,900
TOTAL ASSETS	<u>\$ 8,755,431</u>	<u>\$ 1,355,696</u>	<u>\$ (6,415)</u>	<u>\$ 10,104,712</u>	<u>\$ 2,647,628</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 2,647,628</u>	<u>\$ 12,752,340</u>
LIABILITIES AND NET ASSETS									
CURRENT LIABILITIES									
Grants Payable	\$ 550,000	\$ 50,000	\$ —	\$ 600,000	\$ —	\$ —	\$ —	\$ —	600,000
Accounts Payable and Accrued Expenses	6,635	25,140	—	31,775	—	—	—	—	31,775
Due from Affiliate	—	6,415	(6,415)	—	—	—	—	—	—
Total Current Liabilities	<u>556,635</u>	<u>81,555</u>	<u>(6,415)</u>	<u>631,775</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>631,775</u>
NET ASSETS	<u>8,198,796</u>	<u>1,274,141</u>	<u>—</u>	<u>9,472,937</u>	<u>2,647,628</u>	<u>—</u>	<u>—</u>	<u>2,647,628</u>	<u>12,120,565</u>
TOTAL LIABILITIES AND NET ASSETS	<u>\$ 8,755,431</u>	<u>\$ 1,355,696</u>	<u>\$ (6,415)</u>	<u>\$ 10,104,712</u>	<u>\$ 2,647,628</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 2,647,628</u>	<u>\$ 12,752,340</u>

COMBINING SCHEDULE OF ACTIVITIES

For the Year Ended March 31, 2022

	Without Donor Restriction				With Donor Restriction				Combined Total 2022
	Cancer Research Foundation	Cancer Research Foundation - Chicago Chapter	Eliminations	Total	Cancer Research Foundation	Cancer Research Foundation - Chicago Chapter	Eliminations	Total	
SUPPORT REVENUES									
Contributions	\$ 190,380	\$ 283,510	\$ —	\$ 473,890	\$ —	\$ —	\$ —	\$ —	\$ 473,890
Grants	—	512,000	(45,000)	467,000	—	—	—	—	467,000
Bequests	148,208	—	—	148,208	—	—	—	—	148,208
Event Revenues	—	901,867	—	901,867	—	—	—	—	901,867
Donated Services	—	18,961	—	18,961	—	—	—	—	18,961
Donated Auction Items	—	87,737	—	87,737	—	—	—	—	87,737
Total Support Revenues	<u>338,588</u>	<u>1,804,075</u>	<u>(45,000)</u>	<u>2,097,663</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>2,097,663</u>
OTHER REVENUES									
Interest and Dividends, net	173,086	—	—	173,086	50,380	—	—	50,380	223,466
Net Realized and Unrealized Gain on Investments	454,405	82	—	454,487	153,680	—	—	153,680	608,167
Investment Income, net	<u>627,491</u>	<u>82</u>	<u>—</u>	<u>627,573</u>	<u>204,060</u>	<u>—</u>	<u>—</u>	<u>204,060</u>	<u>831,633</u>
Forfeited Grants	114	—	—	114	—	—	—	—	114
Total Revenues, net	<u>966,193</u>	<u>1,804,157</u>	<u>(45,000)</u>	<u>2,725,350</u>	<u>204,060</u>	<u>—</u>	<u>—</u>	<u>204,060</u>	<u>2,929,410</u>
FUNCTIONAL EXPENSES									
Program Services	772,399	299,602	(45,000)	1,027,001	150,000	—	—	150,000	1,177,001
Supporting Services									
Management and General	39,063	80,628	—	119,691	—	—	—	—	119,691
Fundraising	43,578	78,700	—	122,278	—	—	—	—	122,278
Special Event Fundraising	—	86,290	—	86,290	—	—	—	—	86,290
Total Functional Expenses	<u>855,040</u>	<u>545,220</u>	<u>(45,000)</u>	<u>1,355,260</u>	<u>150,000</u>	<u>—</u>	<u>—</u>	<u>150,000</u>	<u>1,505,260</u>
Excise Taxes Benefit	(16,001)	—	—	(16,001)	—	—	—	—	(16,001)
Total Expenses	<u>839,039</u>	<u>545,220</u>	<u>(45,000)</u>	<u>1,339,259</u>	<u>150,000</u>	<u>—</u>	<u>—</u>	<u>150,000</u>	<u>1,489,259</u>
CHANGE IN NET ASSETS	127,154	1,258,937	—	1,386,091	54,060	—	—	54,060	1,440,151
Net Assets, Beginning	8,071,642	15,204	—	8,086,846	2,593,568	—	—	2,593,568	10,680,414
NET ASSETS, ENDING	<u>\$ 8,198,796</u>	<u>\$ 1,274,141</u>	<u>\$ —</u>	<u>\$ 9,472,937</u>	<u>\$ 2,647,628</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 2,647,628</u>	<u>\$ 12,120,565</u>

COMBINING SCHEDULE OF FUNCTIONAL EXPENSES

For the Year Ended March 31, 2022

	Program Services				Management and General				Supporting Services				Special Event Fundraising				Combined Total 2022
	Cancer Research Foundation - Chicago Chapter		Eliminations	Total	Cancer Research Foundation - Chicago Chapter		Eliminations	Total	Fundraising		Eliminations	Total	Cancer Research Foundation - Chicago Chapter		Eliminations	Total	
	Cancer Research Foundation	Foundation - Chicago Chapter			Cancer Research Foundation	Foundation - Chicago Chapter			Cancer Research Foundation	Foundation - Chicago Chapter			Cancer Research Foundation	Foundation - Chicago Chapter			
Grants	\$ 790,000	\$ 100,000	\$ (45,000)	\$ 845,000	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ 845,000
Payroll and Taxes	97,133	141,356	—	238,489	32,378	47,119	—	79,497	32,377	47,118	—	79,495	—	—	—	—	397,481
Venue, Food and Entertainment	—	—	—	—	—	—	—	—	—	—	—	—	—	66,250	—	66,250	66,250
Legal and Professional	20,062	16,938	—	37,000	5,732	16,939	—	22,671	2,866	8,469	—	11,335	—	—	—	—	71,006
Telephone	481	719	—	1,200	137	719	—	856	69	359	—	428	—	—	—	—	2,484
Postage and Office Supplies	1,635	14,364	—	15,999	467	7,182	—	7,649	234	14,364	—	14,598	—	580	—	580	38,826
Advertising	11,777	3,691	—	15,468	—	1,476	—	1,476	7,852	2,215	—	10,067	—	—	—	—	27,011
Rent	948	2,501	—	3,449	271	5,002	—	5,273	135	5,003	—	5,138	—	—	—	—	13,860
Meeting Expense	—	5,094	—	5,094	—	1,273	—	1,273	—	—	—	—	—	—	—	—	6,367
Insurance	—	471	—	471	—	377	—	377	—	95	—	95	—	—	—	—	943
Newsletter	—	752	—	752	—	—	—	—	—	188	—	188	—	—	—	—	940
Internet	83	964	—	1,047	—	386	—	386	4	579	—	583	—	7,115	—	7,115	9,131
Dues and Subscriptions	—	310	—	310	—	155	—	155	—	310	—	310	—	—	—	—	775
Miscellaneous	280	12,442	—	12,722	78	—	—	78	41	—	—	41	—	12,345	—	12,345	25,186
	\$ 922,399	\$ 299,602	\$ (45,000)	\$ 1,177,001	\$ 39,063	\$ 80,628	\$ —	\$ 119,691	\$ 43,578	\$ 78,700	\$ —	\$ 122,278	\$ —	\$ 86,290	\$ —	\$ 86,290	\$ 1,505,260